Homocysteine, renal disease and cardiovascular disease in a remote Australian Aboriginal community

Internal Medicine Journal

Volumn 35, Issue 5, 2005, Pages 289-294

  McDonald, S ^a,b,c,g   Maguire, G ^a   Duarte, N ^d   Wang, X L ^d,f   Hoy, W ^a,e  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c Australia and New Zealand Dialysis and Transplant Registry   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^g QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Australian Aboriginal; Cardiovascular disease; Homocysteine; Red blood cell folate; Renal disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ABORIGINE; ADULT; AMINO ACID BLOOD LEVEL; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; DNA POLYMORPHISM; ERYTHROCYTE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HOMOZYGOSITY; HUMAN; INTIMA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR;

ADULT; ALBUMINURIA; ARTERIOSCLEROSIS; AUSTRALIA; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; KIDNEY DISEASES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OCEANIC ANCESTRY GROUP; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RURAL POPULATION; VITAMIN B 12;

EID: 18744368137     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2005.00824.x     Document Type: Review

References (46)

1. McDonald SP, Russ GR. Current incidence, treatment patterns and outcome of end-stage renal disease among indigenous groups in Australia and New Zealand. Nephrology 2003; 8: 42-8.
2. Hoy WE, Mathews JD, McCredie DA, Pugsley DJ, Hayhurst BG, Rees M et al. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int 1998; 54: 1296-304.
3. McDonald SP, Maguire GP, Hoy WE. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrol Dial Transplant 2003; 18: 1555-61.
4. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. End-stage renal disease in indigenous Australians: a disease of disadvantage. Ethn Dis 2002; 12: 373-8.
5. Lee AJ, Bonson AP, Yarmirr D, O'Dea K, Mathews JD. Sustainability of a successful health and nutrition program in a remote aboriginal community. Med J Aust 1995; 162: 632-5.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202-6.
7. Wilcken DE, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878-82.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
9. American Diabetes Association and the National Kidney Foundation. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994; 17: 1357-61.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
11. DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-5.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification Diet Renal Dis Study Group. Ann Intern Med 1999; 130: 461-70.
13. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-93. Am J Epidemiol 1997; 146: 483-94.
14. Hosmer D, Lemeshow S. Goodness-of-fit tests for the multiple logistic regression model. Comm Statist 1980; A9: 1043-69.
15. McDonald SP, Maguire GP, Duarte NL, Wang XL, Hoy W. C reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community. Clin Sci (Lond) 2003; 106: 121-8.
16. Shaw JT, McWhinney B, Tate JR, Kesting JB, Marczak M, Purdie D et al. Plasma homocysteine levels in indigenous Australians. Med J Aust 1999; 170: 19-22.
17. Rowley K, O'Dea K, Su Q, Jenkins AJ, Best JD. Low plasma concentrations of diet-derived antioxidants in association with microalbuminuria in Indigenous Australian populations. Clin Sci (Lond) 2003; 105: 569-78.
18. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Laboratory Invest 1996; 56: 41-6.
19. Bostom AG, Kronenberg F, Jacques PF, Kuen E, Ritz E, Konig P et al. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. Atherosclerosis 2001; 159: 219-23.
20. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Dis Assessment Study (CUDAS). Circulation 1999; 99: 2383-8.
21. Silberberg J, Crooks R, Fryer J, Wlodarczyk J, Nair B, Finucane P et al. Fasting and post-methionine homocyst(e)ine levels in a healthy Australian population. Aust NZJ Med 1997; 27: 35-9.
22. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028-35.
23. Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I, Bayindir O. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann Clin Laboratory Sci 2002; 32: 279-86.
24. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32: 23-31.
25. Hsu CY, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int 2002; 61: 1567-76.
26. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJ, Stehouwer CD. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203-9.
27. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998; 41: 684-93.
28. Hultberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelsson B, Agardh CD. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Laboratory Invest 1991; 51: 277-82.
29. Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetol 2002; 39: 183-90.
30. Friedman AN, Hunsicker LG, Selhub J, Bostom AG. Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy. Diabetes Care 2002; 25: 2037-41.
31. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001; 24: 1805-9.
32. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
33. House JD, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat kidney. Biochem J 1997; 328: 287-92.
34. van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K, Stehouwer CD. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54: 166-9.
35. Hoy W, Wang Z, van Buynder P, Baker P, McDonald S, Mathews J. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. Kidney Int 2001; 60: 249-56.
36. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk Communities Study. Circulation 1993; 87: 1107-13.
37. Voutilainen S, Alfthan G, Nyyssonen K, Salonen R, Salonen JT. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med 1998; 30: 300-6.
38. Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, Cassader M et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002; 32: 24-8.
39. Stampfer M, Malinow M, Willett W. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
40. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
41. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-11.
42. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
43. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-10.
44. Hung J, Beilby JP, Knuiman MW, Divitini M. Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. BMJ 2003; 326: 131-6.
45. Hoy WE, Rees M, Kile E, Mathews JD, Wang Z. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. Kidney Int 1999; 56: 1072-7.
46. Rowley K, Walker KZ, Cohen J, Jenkins AJ, O'Neal D, Su Q et al. Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. Med J Aust, 2003; 178: 495-500.